During the first quarter of 2024,
- In their analysis, the DMC will review the safety profile of KL1333 and the potential of the study to achieve statistical significance after the full 48 weeks of dosing, says
Read the full interview with
https://www.biostock.se/en/2024/05/ablivas-ceo-we-remain-on-track-for-the-interim-analysis-early-in-q3/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
https://news.cision.com/abliva/r/ablivas-ceo-to-biostock---we-remain-on-track-for-the-interim-analysis-early-in-q3-,c3991145
(c) 2024 Cision. All rights reserved., source